Vascular Surgery OS
Start learning
← All domains
Clinical topic

Symptomatic Carotid Stenosis

Symptomatic carotid stenosis is narrowing of a carotid artery responsible for an ipsilateral retinal or cerebral ischaemic event within six months. The immediate task is to identify the culprit artery, start medical treatment and decide whether early carotid endarterectomy (CEA) can prevent another stroke safely. Benefit is clearest with 70–99% NASCET stenosis and smaller with 50–69%. The percentage alone is insufficient: symptom timing, infarct burden, neurological recovery and procedural risk determine the decision. [1–3]

Written August 20, 2026 · Mr Razhan K Ali

1 · UNDERSTAND

Attribute the event

Plaque at the bifurcation or proximal internal carotid artery (ICA) usually causes symptoms through thromboembolism; haemodynamic ischaemia is less common and depends on collateral supply. Retinal symptoms occur on the side of the diseased carotid; hemispheric symptoms include contralateral weakness or sensory loss, dysphasia or neglect. Isolated dizziness, syncope or non-focal visual disturbance does not establish carotid causation. [1–3]

Consider competing causes, particularly atrial fibrillation (AF), small-vessel disease, dissection and intracranial disease. “Symptomatic” describes attribution and recency: 50% is a treatment threshold, not part of the definition. A disabling stroke may be carotid-related even when early surgery is unsafe. [1–3]

Confirm the anatomy and brain injury

In acute stroke, obtain emergency brain and vascular imaging through the reperfusion pathway. After suspected TIA, NICE does not recommend routine CT unless an alternative CT-detectable diagnosis is suspected; if MRI is performed after specialist assessment, it should be the same day. [3,4]

Duplex assesses plaque and stenosis using validated laboratory criteria. Before CEA, corroborate duplex with CTA, MRA or a repeat study by a second operator. Before carotid artery stenting (CAS), CTA/MRA should also assess the arch and extra-/intracranial circulation. Resolve discordant studies before intervention. Record the neurological baseline and investigate alternative embolic sources, including ECG and appropriate rhythm monitoring. [1–3]

Report stenosis by NASCET: 100 × (1 − minimum residual ICA diameter / normal distal ICA diameter). ECST uses the estimated original bulb diameter; its percentages are not interchangeable with NASCET. NICE’s treatment bands are 50–99% NASCET or 70–99% ECST. [2–4]

Near-occlusion is different: severe stenosis has reduced the distal ICA calibre, sometimes to a threadlike vessel. Do not calculate an ordinary NASCET percentage using that abnormally small distal artery. [2,3]

2 · DECIDE

Treat the presenting event first

Suspected TIA — which is managed by the medical teams/stroke teams: give aspirin 300 mg immediately, unless contraindicated, and arrange stroke assessment within 24 hours of onset. Do not use ABCD2 to delay assessment. [4]

Persistent neurological deficit: activate the acute stroke pathway; assess thrombolysis/thrombectomy eligibility before considering secondary-prevention CEA. Give aspirin after intracranial haemorrhage is excluded, according to the stroke plan; assess swallowing before oral medication. After IV thrombolysis, the standard pathway withholds antiplatelets and IV heparin for 24 hours after completion, with follow-up imaging before antiplatelets. [3–5]

Select patients for revascularisation

These thresholds apply to attributable symptoms within six months, excluding near-occlusion and complete occlusion, with a documented 30-day procedural stroke/death risk below 6%. [3]

NASCET stenosisDecision
70–99%CEA recommended in suitable patients: ESVS I A. [3]
50–69%Consider CEA: ESVS IIa A. Balance event recency/type, age, sex, functional status, comorbidity and patient preference. [3]
<50%Medical treatment; no routine intervention. Rare recurrent attributable TIA/minor stroke despite best therapy warrants detailed neurovascular investigation and MDT consideration. [3]
Complete ICA occlusionNo routine CEA/CAS for secondary prevention. Acute tandem occlusion belongs to the thrombectomy pathway. [1,3]

Recent hemispheric symptoms generally imply more benefit than remote retinal symptoms. Sex modifies historical benefit estimates but is not a stand-alone exclusion. Frailty and competing illness may outweigh anatomical suitability. [1–3]

Choose the timing and procedure

Operate early when safe. ESVS recommends intervention as soon as possible, preferably within 14 days of symptom onset. The UK/Ireland stroke guideline targets seven days in neurologically stable patients. After a stable non-disabling stroke, SVS recommends intervention once neurologically stable after 48 hours, and before 14 days; expedited treatment does not mean automatic surgery within 48 hours. [3,5,6]

Defer early intervention with disabling stroke (mRS ≥3), infarction exceeding one-third of the ipsilateral MCA territory, or altered consciousness. Reassess after neurological improvement and repeat imaging as appropriate. [3]

After IV thrombolysis—practice divergence: ESVS says a six-day delay should be considered; UK stroke guidance retains a 72-hour deferral. Agree timing with the stroke physician using infarct burden, haemorrhage, recovery and recurrent symptoms—not a single inflexible interval. [3,7]

CEA is preferred, particularly at age ≥70 and during the first 14 days. CAS is an alternative in selected patients, including some with hostile neck anatomy, high lesions, restenosis or substantial surgical risk. Assess arch disease, tortuosity, calcification and access: high risk for CEA does not automatically make CAS safer. Contralateral occlusion and previous radiotherapy require individual assessment. Do not extrapolate transfemoral-CAS trial results to transcarotid artery revascularisation (TCAR). [1–3]

Recognise exceptions

Near-occlusion with distal collapse: no routine CEA/CAS outside a trial. Recurrent ipsilateral symptoms despite best medical therapy may justify intervention after MDT review. Free-floating thrombus: therapeutic anticoagulation; ESVS advises against IV thrombolysis. Recurrent symptoms despite anticoagulation may justify surgical/endovascular removal. [3]

AF with ipsilateral 50–99% stenosis: determine the likely embolic source through neurovascular investigation and MDT review. If ipsilateral events recur despite therapeutic anticoagulation, ESVS recommends CEA or CAS. [3]

Crescendo TIA or stroke-in-evolution: reassess immediately and review brain and vascular imaging with the on-call vascular consultant and stroke consultant to decide treatment and timing. ESVS supports considering urgent CEA, preferably within 24 hours, in selected patients with 50–99% stenosis (IIa C). In contrast, AHA/ASA 2026 finds no functional benefit from emergency CEA within 48 hours for acute ischaemic stroke/unstable neurology caused by high-grade carotid stenosis or occlusion without intracranial occlusion (Class 3: No Benefit; B-NR). These populations overlap but are not identical. Document the imaging and rationale; neither automatic emergency CEA nor a blanket prohibition after isolated TIA is justified. [3,8]

3 · JUSTIFY

CEA removes the embolic source but adds an immediate procedural hazard. Its net benefit therefore depends on untreated stroke risk, delay and the safety of intervention. [1–3]

EvidenceResult and clinical meaning
NASCET 1991: 70–99%Two-year ipsilateral stroke 26% medical versus 9% surgical: large historical benefit in severe symptomatic stenosis. [9]
NASCET 1998: 50–69%Five-year ipsilateral stroke 22.2% versus 15.7%; reported NNT 15: smaller benefit demands careful selection. [10]
Pooled timing analysis, 2004In ≥50% stenosis, five-year NNT 5 when randomised within two weeks of the last event versus 125 after >12 weeks: delay substantially reduces benefit. [11]
CREST symptomatic subgroupPeriprocedural stroke/death 6.0% with transfemoral CAS versus 3.2% with CEA: inspect stroke outcomes, not only composites including MI. [12]

These are historical trial estimates, not a contemporary patient’s untreated prognosis. [1–3]

ECST-2 (2025): the two-year interim analysis included 429 patients with ≥50% stenosis: asymptomatic patients and symptomatic patients with low/intermediate predicted stroke risk. There was no detected advantage from adding revascularisation on its hierarchical clinical/imaging endpoint: win ratio 1.01 (95% CI 0.60–1.70). This supports medical-treatment discussion in selected lower-risk patients; it does not establish equivalence or overturn early CEA for recently symptomatic high-risk disease. [13]

4 · PERFORM

Match antiplatelets to the treatment plan

CEA planned: continue antiplatelets perioperatively and long term using an agreed local protocol. ESVS says combination therapy should be considered after intracranial haemorrhage is excluded; it is not mandatory for everyone. If aspirin monotherapy is chosen, its suggested regimen is 300–325 mg daily for 14 days, then 75–162 mg daily. Do not delay indicated CEA to complete a 21-day DAPT course; the short-term medical DAPT trials excluded patients scheduled for urgent carotid intervention. [3]

No intervention planned after TIA/minor non-cardioembolic stroke: ESVS recommends aspirin plus clopidogrel for 21 days, then clopidogrel alone, or long-term aspirin plus modified-release dipyridamole. Exclude haemorrhage and assess bleeding risk; this is not a blanket regimen for large infarcts or immediately after thrombolysis. [3]

CAS planned: aspirin plus clopidogrel before treatment and for at least four weeks afterwards, then long-term monotherapy. Concurrent anticoagulation needs an individual plan. Long-term aspirin plus clopidogrel is not routine after CEA/CAS without another indication. [3]

UK update: NICE recommends CYP2C19 genotype testing to assess clopidogrel suitability after recent ischaemic stroke/TIA, with shared decision-making and quality assurance for point-of-care testing. Follow the local testing pathway without delaying initial antiplatelets or urgent CEA. [3,14]

Optimise and consent

Provide intensive lipid lowering, smoking cessation, diabetes care and an individual BP plan; avoid abrupt reductions that compromise cerebral perfusion. Add ezetimibe when targets remain unmet on the maximum tolerated statin; consider a PCSK9 inhibitor when indicated. Statin-timing divergence: the UK stroke guideline recommends immediate initiation after TIA/ischaemic stroke; NICE NG128 retains older advice against immediate initiation in acute stroke, while continuing established therapy. Agree and document the stroke plan. [3–5]

Before listing, confirm side, attributable event, stenosis, infarct burden and timing. Review lesion height, previous neck treatment, cardiac fitness, cranial nerve function and antithrombotics. Assess vocal cords when previous contralateral surgery or suspected recurrent laryngeal dysfunction raises the risk of bilateral injury. [1–3,15]

Discuss benefit, medical treatment and appropriate procedural alternatives; document stroke/death, MI, cranial nerve injury, haematoma/airway compromise, hyperperfusion and restenosis/re-intervention. Use current local and patient-specific risks: 6% is a selection ceiling, not a consent estimate. [3,15]

Choose local/regional or general anaesthesia with the patient and anaesthetist; GALA found no significant difference in stroke/MI/death through 30 days after surgery. For conventional CEA, ESVS recommends patch closure, while the underlying trial evidence is of low/very low certainty. [3,16,17]

5 · MANAGE

Monitor neurological status, BP, heart rate, the neck and swallowing after intervention. Treat haemodynamic disturbances promptly; investigate suspected myocardial ischaemia with ECG and troponin. [1,3]

ProblemImmediate action
New deficit in the operated carotid territory immediately after flow restoration during awake CEAImmediate carotid re-exploration for thrombosis or a technical defect. [3]
Deficit on waking from GA or after an initially normal recoveryRapid brain and carotid/intracranial vascular imaging to identify carotid thrombosis, intracranial embolus or haemorrhage and direct rescue. Do not automatically apply the awake clamp-release rule. [3]
Expanding haematoma or airway compromiseContact the on-call vascular and anaesthetic consultants immediately. Arrange airway management and urgent wound decompression/re-exploration in parallel; do not delay for imaging when the airway is threatened. [3,15]
Headache, seizures or neurological deterioration, especially with hypertensionSuspect hyperperfusion/haemorrhage: urgent brain imaging, controlled BP reduction and seizure treatment. [3]
Dysphagia, hoarseness, tongue deviation or lip weaknessAssess cranial nerve and swallowing function; early ENT/swallowing assessment when aspiration or airway compromise is possible. [1–3]

A late neck sinus, bleeding or pseudoaneurysm suggests patch infection: urgent imaging and operative planning, often for patch excision and autologous reconstruction. [1,3]

Follow-up and restenosis

Continue lifelong vascular prevention and give clear instructions for recurrent retinal/cerebral symptoms. ESVS supports selective rather than universal duplex surveillance, considering restenosis risk, contralateral disease and intolerance of carotid flow interruption; agree a documented local schedule. [3]

For late symptomatic 50–99% restenosis, redo CEA or CAS is recommended after MDT review; <50% is generally treated medically. Asymptomatic 70–99% after CEA may justify re-intervention after MDT review; asymptomatic >70% after CAS is generally managed medically. In specified patients with demonstrated neurological/electrophysiological intolerance of carotid flow interruption, ESVS recommends serial surveillance and re-intervention for >70% restenosis even when asymptomatic. [3]

6 · REMEMBER

Attribute the event, confirm the stenosis and assess the brain before choosing the operation. Severe symptomatic disease usually benefits most; moderate disease requires selection. Expedite safe CEA without overlooking large infarcts, thrombolysis or neurological instability. Start medical treatment without delaying indicated CEA. Distinguish postoperative stroke from airway and hyperperfusion emergencies. CEA supplements—never replaces—lifelong vascular prevention. [1–5]

  1. Sidawy AN, Perler BA, editors. Rutherford’s Vascular Surgery and Endovascular Therapy. 10th ed. Elsevier; 2023.
  2. Loftus I, Hinchliffe RJ, editors. Vascular and Endovascular Surgery: A Companion to Specialist Surgical Practice. 7th ed. Elsevier; 2024.
  3. Naylor R, Rantner B, Ancetti S, et al. European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. Eur J Vasc Endovasc Surg. 2023;65:7–111. doi:10.1016/j.ejvs.2022.04.011.
  4. NICE. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management. NG128. 2019; updated 2022. Recommendations.
  5. Intercollegiate Stroke Working Party. National Clinical Guideline for Stroke for the UK and Ireland. 2023. Acute care.
  6. AbuRahma AF, Avgerinos ED, Chang RW, et al. Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease. J Vasc Surg. 2022;75(1S):4S–22S. doi:10.1016/j.jvs.2021.04.073.
  7. Intercollegiate Stroke Working Party. National Clinical Guideline for Stroke for the UK and Ireland. 2023. Long-term management and secondary prevention.
  8. Prabhakaran S, Gonzalez NR, Zachrison KS, et al. 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2026;57:e316–e436. doi:10.1161/STR.0000000000000513.
  9. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325:445–53. doi:10.1056/NEJM199108153250701.
  10. Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med. 1998;339:1415–25. doi:10.1056/NEJM199811123392002.
  11. Rothwell PM, Eliasziw M, Gutnikov SA, Warlow CP, Barnett HJ. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet. 2004;363:915–24. doi:10.1016/S0140-6736(04)15785-115785-1).
  12. Silver FL, Mackey A, Clark WM, et al. Safety of stenting and endarterectomy by symptomatic status in CREST. Stroke. 2011;42:675–80. doi:10.1161/STROKEAHA.110.610212.
  13. Donners SJA, van Velzen TJ, Cheng SF, et al. Optimised medical therapy alone versus optimised medical therapy plus revascularisation for asymptomatic or low-to-intermediate risk symptomatic carotid stenosis (ECST-2): 2-year interim results of a multicentre randomised trial. Lancet Neurol. 2025;24:389–99. doi:10.1016/S1474-4422(25)00107-300107-3).
  14. NICE. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack. HTG724 (formerly DG59). 2024. Guidance.
  15. Chaikof EL, Cambria RP, editors. Atlas of Vascular Surgery and Endovascular Therapy: Anatomy and Technique. Saunders; 2014.
  16. GALA Trial Collaborative Group. General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre, randomised controlled trial. Lancet. 2008;372(9656):2132–42. doi:10.1016/S0140-6736(08)61699-261699-2).
  17. Orrapin S, Benyakorn T, Siribumrungwong B, Rerkasem K. Patch angioplasty versus primary closure for carotid endarterectomy. Cochrane Database Syst Rev. 2022;8:CD000160. doi:10.1002/14651858.CD000160.pub4.